The funds will support regulatory activities and the planned 510(k) submission for approval to the U.S. Food and Drug Administration (FDA) for Flexi-Port ™ SLF-TANL ™, a novel subcutaneous port ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback